Published online Jan 28, 2015. doi: 10.3748/wjg.v21.i4.1140
Peer-review started: June 22, 2014
First decision: July 21, 2014
Revised: August 22, 2014
Accepted: September 29, 2014
Article in press: September 30, 2014
Published online: January 28, 2015
Processing time: 219 Days and 18.5 Hours
AIM: To investigate the clinicopathological significance and prognostic value of caveolin-1 (CAV-1) in both tumor and stromal cells in colorectal cancer (CRC).
METHODS: A total of 178 patients with CRC were included in this study. The correlation between CAV-1 expression and clinicopathologic features and survival was studied.
RESULTS: CAV-1 expression was detected in tumor and stromal cells. The expression of stromal CAV-1 was closely associated with histological type (P = 0.022), pathologic tumor-node-metastasis stage (P = 0.047), pathologic N stage (P = 0.035) and recurrence (P = 0.000). However, tumor cell CAV-1 did not show any correlation with clinical parameters. Additionally, the loss of stromal CAV-1 expression was associated with shorter disease-free survival (P = 0.000) and overall survival (P = 0.000). Multivariate analysis revealed that the loss of stromal CAV-1 expression was an independent prognostic factor for both overall survival (P = 0.014) and disease-free survival (P = 0.006).
CONCLUSION: The loss of stromal CAV-1 expression in CRC was associated with poor prognosis and could be a prognostic factor for CRC patients.
Core tip: Caveolin-1 (CAV-1), an essential structural protein of the endocytic caveolae plasma membrane, plays a major role in modulating tumorigenic processes. Recent studies have revealed that the loss of stromal CAV-1 results in an activated tumor microenvironment and is significantly related to tumor recurrence and a poor prognosis for many tumors. However, the association between CAV-1 and colorectal cancer remains unknown. In our study, we observed CAV-1 expression in both tumor and stromal cells. Our results demonstrate that the loss of stromal CAV-1 is an independent predictor of poor overall survival and disease-free survival, whereas CAV-1 expression in tumor cells has no prognostic value.